Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20592123 | 0.90 | LTA4H (0.52) | LTA4HCCR1 | |
| SCHEMBL24050339 | 0.82 | CARM1 (0.60) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL20592122 | 0.81 | SMN1; SMN2 (0.47) | LTA4HSIGMAR1CCR1 | |
| SCHEMBL21064084 | 0.81 | LTA4H (0.56) | LTA4HKDM1AEPHX2 | |
| SCHEMBL4229314 | 0.81 | LTA4H (0.80) | LTA4HSIGMAR1DRD2KDM1A | |
| Hydrochloric Acid SCHEMBL20592194 | 0.80 | LTA4H (0.55) | LTA4HKDM1AEPHX2 | |
| SCHEMBL18361352 | 0.80 | LTA4H (0.55) | LTA4HEPHX2 | |
| SCHEMBL1542507 | 0.79 | HCAR3 (0.58) | LTA4H | |
| SCHEMBL14980367 | 0.79 | POLB (0.61) | LTA4HEPHX2 | |
| SCHEMBL15305255 | 0.79 | TRPA1 (0.59) | SIGMAR1DRD2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2021-01-14 | — | — | US | disclosed |
| US-10851058-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2018-12-27 | — | — | US | disclosed |
| WO-2017004522-A1 | HISTONE DEACETYLASE INHIBTORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851058-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | LTA4H 2846/4885SIGMAR1 4438/4885DRD2 3565/4885 |
| US-20210009519-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | LTA4H 2846/4885SIGMAR1 4438/4885DRD2 3565/4885 |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | LTA4H 2846/4885SIGMAR1 4438/4885DRD2 3565/4885 |
| US-10308608-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | LTA4H 2846/4885SIGMAR1 4438/4885DRD2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.